The role of levosimendan as inotropic agents in patients with LV dysfunction admitted to ICU post cardiac surgery

Mohamed Salah Eldeen Hussein; Ahmed Abdel Rahman Batah; Nael Samir Selit; Mohamed Fawzy Ablelaleem

doi:10.53730/ijhs.v6nS3.5319

Authors

Mohamed Salah Eldeen Hussein
MSalaheldeenhussein@gmail.com
Departement of Critical Care Medicine, Faculty of Medicine, Cairo University, Egypt
Ahmed Abdel Rahman Batah Departement of Critical Care Medicine, Faculty of Medicine, Cairo University, Egypt
Nael Samir Selit Departement of Critical Care Medicine, Faculty of Medicine, Cairo University, Egypt
Mohamed Fawzy Ablelaleem Departement of Critical Care Medicine, Faculty of Medicine, Cairo University, Egypt

Keywords:

levosimendan, LV dysfunction, cardiac surgery, inotropic support, low cardiac output

Abstract

BACKGROUND: Coronary artery bypass graft (CABG) surgery is the standard of care for the management of patients with three-vessel and left main coronary artery disease (CAD) with viable myocardium. Positive inotropic agents are the treatment of choice in patients with LV dysfunction post CABG. Levosimendan is an inotropic drug that has three major mechanisms of action: positive inotropy, vasodilation, and cardiac cytoprotection. Levosimendan is a calcium sensitizer, it improves myocardial contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption and without impairing relaxation and diastolic function. AIM: The aim of this study was to determine the effect of levosimendan compared to the conventional inotropic agents on the outcomes of patients with LV dysfunction undergoing CABG. METHODS: It is a prospective observational study that patients were divided into 2 groups of 50 patients each. Group A received intravenous levosimendan (at a dose of 0.2μg per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1μg per kilogram per minute for 23 hours), with the infusion started at the induction of anesthesia while Group B which included patients who received conventional drugs. Clinical examination, Hemodynamic data and Laboratory investigations pre-operative and post-operative were collected.

Downloads

Download data is not yet available.

References

Levin, R., Degrange, M., Del Mazo, C., et al. (2012). Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol; 17:125–30.

Lomivorotov, V., Efremov, S., Kirov, M., et al. (2017). Low-Cardiac-Output Syndrome After Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 31(1):291-308.

Cleland JG,FreemantleN,ColettaAP,et al (2006): Clinicaltrialsupdate from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA,REVIVE-II,SURVIVE,andPROACTIVE. European Journal ofHeartFailure 8:105-110.

Zangrillo, A., Alvaro, G., Pisano, A., et al. (2016). A randomized controlled trial of levosimendan to reduce mortality in high-risk cardiac surgery patients (CHEETAH): rationale and design, Am. Heart J; 177 (2016) 66–73.

Terbeck, S., Heinisch, P.P., Lenz, A., et al. (2019). Levosimendan and systemic vascular resistance in cardiac surgery patients: a systematic review and meta-analysis. Sci Rep; 9: 20343.

Hansen, M.S., Andersen, A. and Nielsen-Kudsk, E. (2018). Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ; 8(3): 2045894018790905.

Cholley, B., Caruba, T., Grosjean, S., et al. (2017). Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. JAMA; 318(6):548–556.

Huang, X., Lei, S., Zhu, M.F., et al. (2013). Levosimendan versus dobutamine in critically ill patients: ameta-analysis of randomized controlled trials. J Zhejiang Univ Sci B; 14(5):400–15.

Barisin S, Husedzinovic I, Sonicki Z, et al.(2004) Levosimendan in off-pump coronary bypass: a four times masked controlled study. J Cardiovasc Pharmacol. 2004; 44:703-8.

Jawitz, O., Stebbins, A., Raman, V., et al. (2021). Association between levosimendan, postoperative AKI, and mortality in cardiac sur ger y: Insights from the LEVO-CTS trial. Am Heart J; 231:18–24.

Lannemyr, L., Ricksten, S., Rundqvist, B., et al. (2018). Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial. Journal of the American Heart Association; 7.

Guerrero-Orriach, J., Malo-Manso, A., Ramirez-Aliaga, M., et al. (2020). Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients with Low Cardiac Output Syndrome after Cardiac Surgery: Clinical Trial FIM-Front. Pharmacol; 11:1331.

Papp, Z., Édes, I. and Fruhwald, S. (2012). Levosimendan: Molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan. International Journal of Cardiology; 159: 82–87.

Wang, W., Zhou, X. and Liao, X. (2019). The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta‑analysis. Journal of Anesthesia (2019); 33:543–550.

Zangrillo, A., Alvaro, G., Belletti, A., et al., (2018). Effect of levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: a substudy of a multicenter randomized trial. J. Cardiothorac Vasc Anesth; 32(5):2152–9.

Maharaj, R. and Metaxa V. (2011). Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomized controlled trials. Crit Care; 15: 140.

Soeding, P.E., Royse, C.F., Wright, C.E., et al. (2007). Inoprotection: the perioperative role of levosimendan. Anaesthesia and intensive care; 35(6): 845–862.

Zangrillo, A., Putzu, A., Monaco, et al. (2015). Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. Journal of critical Care, 30(5): 908–913.

Packer, M., Colucci, W. and Fisher, L. (2013). Effect of Levosimendan on the Short-Term Clinical Course of Patients with Acutely Decompensated Heart Failure. JACC: Heart Failure, 1(2): 103-111.

Nieminen, M. S., Fruhwald, S., Heunks, L. M., et al. (2013). Levosimendan: current data, clinical use and future development. Heart Lung and Vessels; 5(4): 227–245.

Mebazaa, A., Nieminen, MS., Filippatos, G.S., et al. (2009). Levosimendan vs. dobutamine: outcomes for acute heart failure patients on betablockers in SURVIVE. Eur J Heart Fail; 11: 304-11.